investorscraft@gmail.com

AbCellera Biologics Inc. (ABCL)

Previous Close
$3.61
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)39.27988
Intrinsic value (DCF)1.94-46
Graham-Dodd Method0.66-82
Graham Formula8.31130

Company Information

2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
Phone: 604 559 9005
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Carl L.G. Hansen Ph.D.
Full Time Employees: 596

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

HomeMenuAccount